Literature DB >> 33490858

Benefits and limitations of sting challenge in hymenoptera venom allergy.

Katharina Aßmus1, Markus Meissner1, Roland Kaufmann1, Eva Maria Valesky1.   

Abstract

The prevalence of systemic reactions to hymenoptera stings is up to 7.5%. Venom-specific immunotherapy (VIT) is an established treatment for insect venom allergy. In order to monitor the allergic status and thus the success of the therapy, controlled sting challenge under VIT continues to be the gold standard. This review deals not only with useful indications and therapeutic consequences but also with critical aspects that should be considered when performing sting challenge. © Dustri-Verlag Dr. K. Feistle.

Entities:  

Keywords:  hymenoptera venom allergy; risk factors; sting challenge; therapy failure

Year:  2021        PMID： 33490858      PMCID： PMC7814776          DOI： 10.5414/ALX02148E

Source DB:  PubMed          Journal:  Allergol Select        ISSN： 2512-8957


  31 in total

1.  Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy.

Authors:  P Korošec; K Žiberna; M Šilar; M Dežman; N Čelesnik Smodiš; M Rijavec; P Kopač; R Eržen; N Lalek; N Bajrović; M Košnik; M Zidarn
Journal:  Clin Exp Allergy       Date:  2015-10       Impact factor: 5.018

2.  Hymenoptera sting challenge of 348 patients: relation to subsequent field stings.

Authors:  H K van Halteren; P W van der Linden; S A Burgers; A K Bartelink
Journal:  J Allergy Clin Immunol       Date:  1996-05       Impact factor: 10.793

3.  The Hymenoptera venom study. III: Safety of venom immunotherapy.

Authors:  R F Lockey; P C Turkeltaub; E S Olive; J M Hubbard; I A Baird-Warren; S C Bukantz
Journal:  J Allergy Clin Immunol       Date:  1990-11       Impact factor: 10.793

4.  Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.

Authors:  F Ruëff; A Wenderoth; B Przybilla
Journal:  J Allergy Clin Immunol       Date:  2001-12       Impact factor: 10.793

5.  Survey of patients after discontinuing venom immunotherapy.

Authors:  D B Golden; A Kagey-Sobotka; L M Lichtenstein
Journal:  J Allergy Clin Immunol       Date:  2000-02       Impact factor: 10.793

6.  Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.

Authors:  H K van Halteren; P W van der Linden; J A Burgers; A K Bartelink
Journal:  J Allergy Clin Immunol       Date:  1997-12       Impact factor: 10.793

Review 7.  Epidemiology of Hymenoptera allergy.

Authors:  Leonardo Antonicelli; M Beatrice Bilò; Floriano Bonifazi
Journal:  Curr Opin Allergy Clin Immunol       Date:  2002-08

8.  Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis.

Authors:  R E Reisman
Journal:  J Allergy Clin Immunol       Date:  1993-12       Impact factor: 10.793

9.  Clinical and immunologic follow-up of patients who stop venom immunotherapy.

Authors:  M U Keating; A Kagey-Sobotka; R G Hamilton; J W Yunginger
Journal:  J Allergy Clin Immunol       Date:  1991-09       Impact factor: 10.793

10.  EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy.

Authors:  G J Sturm; E-M Varga; G Roberts; H Mosbech; M B Bilò; C A Akdis; D Antolín-Amérigo; E Cichocka-Jarosz; R Gawlik; T Jakob; M Kosnik; J Lange; E Mingomataj; D I Mitsias; M Ollert; J N G Oude Elberink; O Pfaar; C Pitsios; V Pravettoni; F Ruëff; B A Sin; I Agache; E Angier; S Arasi; M A Calderón; M Fernandez-Rivas; S Halken; M Jutel; S Lau; G B Pajno; R van Ree; D Ryan; O Spranger; R G van Wijk; S Dhami; H Zaman; A Sheikh; A Muraro
Journal:  Allergy       Date:  2017-12-05       Impact factor: 13.146
View more
  2 in total

1.  Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy.

Authors:  Tamara Eitel; Kim Nikola Zeiner; Katharina Assmus; Hanns Ackermann; Nadja Zoeller; Markus Meissner; Roland Kaufmann; Stefan Kippenberger; Eva Maria Valesky
Journal:  World Allergy Organ J       Date:  2021-04-21       Impact factor: 4.084

Review 2.  Hymenoptera Venom Immunotherapy: Immune Mechanisms of Induced Protection and Tolerance.

Authors:  Ajda Demšar Luzar; Peter Korošec; Mitja Košnik; Mihaela Zidarn; Matija Rijavec
Journal:  Cells       Date:  2021-06-22       Impact factor: 6.600
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.